PLX038 PEG-SN-38 Dosing Schedule for Safer PARP Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Combination therapies of PARP inhibitors with Top1 inhibitors face dose-limiting toxicities, limiting their clinical utility, and identifying appropriate dosing schedules for long-acting Topoisomerase I inhibitors like PLX038 with DNA damage response inhibitors is challenging to achieve desired efficacy and safety.
Innovation Solution
Administer PLX038, a 4-armed PEG-SN-38 conjugate, at specific doses every three weeks, allowing it to accumulate in tumors and release SN-38 slowly, while minimizing plasma levels to avoid toxicity, and combine it with DDR inhibitors like PARP inhibitors in a gapped schedule.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy of PARP inhibitors with Top1 inhibitors is used, then anti-tumor efficacy is improved, but dose-limiting toxicities increase
Solution Approach 1:
The patent implements a gapped dosing schedule where the Top1 inhibitor is administered first and allowed to accumulate in tumors and clear from normal tissues before the PARP inhibitor is introduced. This preliminary action of selective tumor accumulation creates a temporal window where tumor cells are damaged but normal cells have recovered, thereby improving the therapeutic ratio while maintaining combination efficacy
Solution Approach 2:
The patent employs periodic administration cycles with specific gaps between Top1 inhibitor and PARP inhibitor doses. This periodic action allows the system to oscillate between tumor targeting phases and normal tissue recovery phases, maintaining sustained anti-tumor pressure while preventing cumulative toxicities from building up to dose-limiting levels
2Quantity of substance
If both DNA damaging agent and PARP inhibitor are concomitantly administered, then maximal systemic exposure of both drugs is achieved, but toxicities increase and dose reductions are required
Solution Approach 1:
The Top1 inhibitor is administered in advance and given time to selectively accumulate in tumor tissue before the PARP inhibitor is introduced. This preliminary tumor targeting action ensures that when the PARP inhibitor is subsequently administered, the majority of DNA damage occurs in tumor cells rather than normal cells, thereby maintaining high effective exposure while reducing toxicities
Solution Approach 2:
The gapped dosing schedule creates local quality differences in drug distribution and effect over time. The Top1 inhibitor preferentially accumulates in tumor tissue during the gap period, creating a localized high-concentration zone. When the PARP inhibitor is subsequently administered, this localized tumor concentration ensures that the combination effect is concentrated where needed (in tumors) rather than uniformly distributed throughout the body, thereby reducing systemic toxicities
3Reliability
If gapped schedule is used to administer Top1 inhibitor then PARP inhibitor, then selective tumor inhibition is achieved, but pharmacokinetic profiles of the two agents often preclude the use of gapped schedule
Solution Approach 1:
The patent modifies the dosing parameters of the Top1 inhibitor by using extended interval scheduling (e.g., administering every 3 weeks rather than more frequently) and adjusting the gap duration based on the specific pharmacokinetic properties of each drug combination. These parameter changes allow the gapped schedule to be adapted to different pharmacokinetic profiles, making the approach versatile across multiple agent combinations while maintaining selective tumor inhibition
Solution Approach 2:
The dosing schedule is made dynamic rather than fixed, with the gap duration and dosing intervals adjusted based on the specific pharmacokinetic characteristics of the Top1 inhibitor and PARP inhibitor being combined. This dynamic adaptation allows the regimen to be optimized for each specific drug pair, accommodating varying elimination half-lives and tissue distribution patterns while preserving the selective tumor inhibition benefit of the gapped approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves high tumor exposure to SN-38 without systemic toxicity, enabling effective cancer treatment with improved therapeutic index and safety profile, particularly in BRCA-deficient tumors.
Implementation Method 1
The prodrug slowly releases SN-38, and has long species-specific elimination tin values of ~20 hr in mice and ~5 days in humans. Using PLX038, it has been shown that within the tumor environment SN-38 is slowly released over periods of several weeks, substantially increasing tumor exposure to the active drug.
Data Source
AI summary
The disclosure provides method of treating cancer in a patient in need thereof, comprising safely and efficaciously administering to the patient PLX038, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLX038 with inhibitors of the DNA damage response (DDR).